FMP
Marker Therapeutics, Inc.
MRKR
NASDAQ
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
2.16 USD
-0.3 (-13.89%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2.83B
2.79B
2.91B
3.34B
2.71B
2.69B
2.68B
2.67B
2.66B
2.65B
-
-1.59
4.37
14.63
-18.94
-0.38
-0.38
-0.38
-0.38
697M
719M
629M
1.47B
885M
801.69M
798.64M
795.61M
792.59M
789.58M
24.59
25.78
21.61
44.05
32.72
29.75
29.75
29.75
29.75
-117M
-171M
-206M
-190M
-113M
-146.63M
-146.08M
-145.52M
-144.97M
-144.42M
-4.13
-6.13
-7.08
-5.69
-4.18
-5.44
-5.44
-5.44
-5.44
580M
548M
423M
1.28B
772M
655.05M
652.56M
650.09M
647.62M
645.16M